All Updates

Today, the American Cancer Society Cancer Action Network (ACS CAN) sent a letter to key Congressional leaders urging them to advance legislation that comprehensively addresses the nation’s ongoing drug shortage crisis ahead of a Senate Finance Committee hearing Tuesday.

Today, the American Cancer Society Cancer Action Network (ACS CAN) sent a letter to key Congressional leaders urging them to advance legislation that comprehensively addresses the nation’s ongoing drug shortage crisis ahead of a Senate Finance Committee hearing Tuesday.

December 1 is a monumental day for North Carolina. The Tar Heel State should feel a sense of pride and relief for the nearly 600,000 North Carolinians who are now eligible for affordable health insurance through Medicaid. We at the American Cancer Society Cancer Action Network (ACS CAN) are thrilled

COLUMBIA, S.C. – November 30, 2023 – As North Carolina expands Medicaid December 1, the American Cancer Society Cancer Action Network (ACS CAN) calls on South Carolina lawmakers to offer the same benefits to the people of the Palmetto State. “It’s long past time to offer access to critical,

RALEIGH, N.C. – November 30, 2023 – The American Cancer Society Cancer Action Network (ACS CAN) recognizes a monumental day for all North Carolinians for which they can take pride and have a sense of relief for the nearly 600,000 people who will now have access to affordable, quality

LAKE SUCCESS, NY – November 27, 2023 – Local health care providers, cancer survivors, and patient advocates gathered today at the Northwell Health Cancer Institute to call on Governor Kathy Hochul to prioritize health equity by improving access to biomarker testing and signing Senate Bill 1196a / Assembly Bill 1673a

WASHINGTON, DC – November 20, 2023 – Grail, LLC announced this morning that the Centers for Medicare and Medicaid Services (CMS) and Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) study for the company’s Galleri multi-cancer early detection (MCED) test to evaluate the technology’s capacity to reduce

WASHINGTON, DC – November 20, 2023 – Grail, LLC announced this morning that the Centers for Medicare and Medicaid Services (CMS) and Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) study for the company’s Galleri multi-cancer early detection (MCED) test to evaluate the technology’s capacity to reduce